Unknown

Dataset Information

0

Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study.


ABSTRACT: BACKGROUND:Preclinical data have suggested a therapeutic role of JUN pathway activation in dedifferentiated liposarcoma (DDLPS) tumorigenesis. Aplidin is a drug inducing apoptosis through a strong, sustained activation of c-Jun NH2-terminal kinase. METHODS:This phase II trial included patients with progressive advanced DDLPS. They received Aplidin 5 mg/m(2) days 1-15, 28-day cycle until disease progression or unacceptable toxicity. The primary end point was the 3-month nonprogression rate (PFS3) defined as the proportion of patients with nonprogressive disease at 3 months. A PFS3 of 40% considered as a reasonable objective to claim drug efficacy. RESULTS:Between August 2012 and May 2013, 24 patients were included. Sixteen had received prior chemotherapy. Twenty-two were assessable for efficacy. The PFS3 was 9.1% [95% confidence interval (CI) 1.1-29.2]. Median progression-free and overall survivals were 1.6 months (95% CI 1.4-2.6) and 9.2 months (95% CI 6.6-). The most frequent adverse events of any grade were nausea, fatigue, anorexia, vomiting and diarrhea. CONCLUSION:Aplidin did not meet the primary end point of this trial and do not deserve further investigation in DDLPS. CLINICALTRIALSGOV IDENTIFIER:NCT01876043.

SUBMITTER: Toulmonde M 

PROVIDER: S-EPMC4478976 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study.

Toulmonde M M   Le Cesne A A   Piperno-Neumann S S   Penel N N   Chevreau C C   Duffaud F F   Bellera C C   Italiano A A  

Annals of oncology : official journal of the European Society for Medical Oncology 20150603 7


<h4>Background</h4>Preclinical data have suggested a therapeutic role of JUN pathway activation in dedifferentiated liposarcoma (DDLPS) tumorigenesis. Aplidin is a drug inducing apoptosis through a strong, sustained activation of c-Jun NH2-terminal kinase.<h4>Methods</h4>This phase II trial included patients with progressive advanced DDLPS. They received Aplidin 5 mg/m(2) days 1-15, 28-day cycle until disease progression or unacceptable toxicity. The primary end point was the 3-month nonprogress  ...[more]

Similar Datasets

| S-EPMC3811907 | biostudies-literature
| S-EPMC3286175 | biostudies-literature
| S-EPMC3749588 | biostudies-literature
| S-EPMC8424216 | biostudies-literature
| S-EPMC4576908 | biostudies-literature
| S-EPMC7939029 | biostudies-literature
| S-EPMC8763616 | biostudies-literature
| S-EPMC5696191 | biostudies-literature
| S-EPMC7139289 | biostudies-literature
| S-EPMC5035789 | biostudies-literature